FDA approves GSK hepatitis B drug with higher cure rates

The U.S. Food and Drug Administration has approved GSK's hepatitis B drug, which successfully extended functional cures to significantly more patients than previous treatment methods. The approval marks a major advancement in hepatitis B care, as the drug demonstrated superior efficacy in achieving sustained viral suppression and reducing disease progression compared to existing therapies. This regulatory win strengthens GSK's infectious disease portfolio and offers a new treatment option for the millions of people worldwide living with chronic hepatitis B infection.